Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for global professionals · Monday, June 25, 2018 · 452,975,534 Articles · 3+ Million Readers

Cytomedix Buys Sorin's Blood Separation System

April 17, 2010 (FinancialWire) — Cytomedix, Inc. (AMEX: GTF) has closed an agreement with Sorin Group to acquire the Angel Whole Blood Separation System and activAT Autologous Thrombin Processing Kit for $7 million in cash, to be paid in installments over the next two and one-half years.

Together these products had sales of approximately $5 million in 2009, of which over 90% were from high-margin, single-use disposable products.

The company also has raised gross proceeds of $3.65 million in a private placement of securities with both new and existing stockholders. Under the terms of the private placement, Cytomedix issued 3,650 shares of a $1,000 stated value preferred stock that is convertible into the company's common stock at $0.44 per share and carries a 10% annual dividend to be paid quarterly in cash or common stock at the company's option.

In addition, the company issued 4,128,631 warrants to purchase its common stock, exercisable at $0.54 per share. The warrants are exercisable immediately and expire on April 9, 2015. The proceeds from this private placement are being used to fund the Sorin asset purchase and for general corporate and working capital purposes.

Used primarily in operating rooms, the Angel Whole Blood Separation System consists of a blood processing device and disposable products used for separation of whole blood into red cells, platelet poor plasma and platelet rich plasma (PRP). The Angel System received market clearance from the U.S. Food and Drug Administration (FDA) in August 2005.

The activAT Kit is designed to produce autologous thrombin serum from platelet poor plasma. The activAT kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products.

Maxim Group LLC served as financial advisor to Cytomedix on this transaction.

Sorin Group is a global, medical device company and a leader in the treatment of cardiovascular diseases.

Cytomedix is a biotechnology company that develops, sells, and licenses regenerative biological therapies, to primarily address the areas of wound care, inflammation, and angiogenesis.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[frlylrf] [biomedphrm] [mrgrsacqstns]

Powered by EIN Presswire